12:00 AM
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Toca 511: Phase I started

Tocagen began an open-label, U.S. Phase I trial to evaluate up to 4 single ascending-doses of Toca 511 injected into the resection cavity of about 15 patients with recurrent...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >